5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C 1-4 alkyl n nuseful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.